Products
Online Inquiry
Fruquintinib (HMPL-013)
Cat. No.:
OB0225WX-2631
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Fruquintinib is a highly selective VEGFR family inhibitor with IC50 values of 33 nM, 35 nM, and 0.5 nM for VEGFR 1, 2, and 3, respectively, while showing minimal potency against c-kit, FGFR-1, and RET.
Synonym:
Fruquintinib; 1194506-26-7; HMPL-013; Fruzaqla; HMPL013; 6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide; Fruquintinibum; Elunate; 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide; 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide; 6-(6,7-dimethoxyquinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide; GTPL9428; 3-Benzofurancarboxamide, 6-((6,7-dimethoxy-4-quinazolinyl)oxy)-N,2-dimethyl-; 6-[(6,7-Dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-3-benzofurancarboxamide; 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethyl-1-benzofuran-3-carboxamide
CAS No.:
1194506-26-7
Compound CID:
44480399
Formula:
C21H19N3O5
Formula Weight:
393.39
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Fruquintinib is employed in oncology research as a highly selective inhibitor of VEGFR 1/2/3 to investigate the disruption of tumor-induced angiogenesis and the suppression of malignant growth.
Library Information
Target:
VEGFR
Receptor:
VEGFR
Pathways:
Angiogenesis
Plate Number:
L6700-07
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
6 mg/mL; 15.25 mM
Water Max Solubility:
˂1 mg/mL
Ethanol Max Solubility:
˂1 mg/mL
ALogP:
3.111
HBA_Count:
7
HBD_Count:
1
Rotatable Bond:
5
